Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Orchestra BioMed receives $20M from Medtronic to support pivotal trial for hypertension therapy.
MDT
$81.21
+$1.91 +2.41%

Orchestra BioMed receives $20M from Medtronic to support pivotal trial for hypertension therapy.

Company Fundamentals
06 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Orchestra BioMed secured a $20 million payment from Medtronic under a prior financing agreement to fund the completion of the BACKBEAT Trial, which tests AVIM Therapy for uncontrolled hypertension in pacemaker patients. This payment, combined with $15 million from Ligand, totals $35 million in strategic capital aimed at advancing regulatory and commercialization goals. AVIM Therapy is an investigational bioelectronic treatment designed to lower blood pressure in patients with hypertensive heart disease using pacemakers. The collaboration with Medtronic supports the development and potential FDA approval of this innovative therapy, which could benefit millions of patients with uncontrolled hypertension.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App